Zhejiang Ausun Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Zhiguo Zheng
Chief executive officer
CN¥1.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.1yrs |
| CEO ownership | 50.6% |
| Management average tenure | no data |
| Board average tenure | 10yrs |
Recent management updates
Recent updates
What Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) 28% Share Price Gain Is Not Telling You
Jan 06
Is Zhejiang Ausun Pharmaceutical (SHSE:603229) Using Too Much Debt?
Dec 20There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise
Oct 08Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet
Jul 31Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified
Mar 06CEO
Zhiguo Zheng (53 yo)
10.1yrs
Tenure
CN¥1,121,600
Compensation
Mr. Zhiguo Zheng serves as Chairman and General Manager of Zhejiang Ausun Pharmaceutical Co., Ltd. Mr. Zheng served as Member of Supervisory Board at Zhejiang Hai Xiang Pharmaceutical Company Limited. He h...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 10.1yrs | CN¥1.12m | 50.64% CN¥ 3.5b | |
| Accounting Supervisor & Director | 10.1yrs | CN¥302.60k | no data | |
| Deputy GM & Director | 10.1yrs | CN¥556.90k | 0.65% CN¥ 45.2m | |
| Director | 10yrs | no data | no data | |
| Chairman of Supervisory Board | 9.8yrs | no data | no data | |
| Director | 4.7yrs | CN¥340.20k | no data |
10.0yrs
Average Tenure
45.5yo
Average Age
Experienced Board: 603229's board of directors are seasoned and experienced ( 10 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 23:43 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Ausun Pharmaceutical Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Feifei Xu | China Merchants Securities Co. Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |
| Jiaxi Xu | Industrial Securities Co. Ltd. |